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Abstract 
Introduction: In Ethiopia, hepatocellular carcinoma (HCC) is the most common cancer with 100% fatality rate. 
HCC cases in low income countries die within few months following diagnosis. There is lack of information on 
the burden, risk factors, diagnosis modalities, surveillance strategies and treatment approaches to HCC in Ethiopia.  
Objective: To analyze the existing evidence related to burden, risk factors, diagnosis modalities, surveillance 
strategies, and treatment and prevention strategies of HCC in Ethiopia. 
Methods: All studies done on HCC in Ethiopian irrespective of year of publication and study types were included. 
Literatures were retrieved from electronic database of PubMedand Cochrane library during September/2016 to 
January 2/2017. Key words and mesh terms such as ‘hepatocellular carcinoma’, ‘hcc’, ‘hepatoma’, ‘malignant 
hepatoma’, ‘hepatocarcinoma’ were used to search for documents. Besides, we searched for articles, guidelines 
and reviews from world health organizations, lancet and Google scholar sites. Each of the retrieved studies was 
assessed by two authors for inclusion based on the eligibility criteria, and for quality using the critical appraisal 
checklist. Qualitative data were synthesized for analyzing the theories of studies. Medley reference manager was 
used to manage citations. 
Results: A total of 1448 literatures were retrieved. Eight studies fulfill the eligibility criteria, however, only three 
were full-fledged articles. HCC is clinically characterized by exhaustion, loss of appetite, rapid loss of weight, 
epigastric pain, right upper abdominal quadrant pain with a rapidly growing mass, jaundice, and ascites with or 
without hepatomegaly and splenomegaly. Data on HCC proportion among liver disease patients lies between 
16.1%-19.2%. Cirrhosis followed by hepatotoxic indigenous drugs and viral hepatitis were found to be as major 
risk factor for HCC. In Ethiopia, there is no surveillance activity and no standard staging systems. Furthermore, 
there was no policy frame -work for management of HCC. 
Conclusion: As compared to other countries, Ethiopia is far behind in addressing HCC. There is no national 
policy framework and guideline for the management of HCC. Moreover, HCC is a neglected cancer that is 
considered as a death penalty by the community. Health professionals working in health facilities and health 
offices should share the data they have to the scientific community and policy makers, for further searching 
solutions and informed decision, respectively. An intensified public health strategy on health education and early 
case detection is of critical importance. In addition concerted effort should be made to develop HCC prevention 
and treatment modality.  [Ethiop. J. Health Dev.  2017;31(1):44-56] 
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Introduction 
In 2013, there were 792,000 incidence  of liver cancer 
globally and 818,000 deaths with 44-86% occurrence 
in developing countries (1,2). Liver cancer is the fifth 
incident cases and second cause of mortality in 
developing countries (1–4) but there is still no 
comprehensive description of the current status of its 
epidemiology in Africa (5).  Mozambique is the highest 
burden of HCC in Africa; studies showed that HCC has 
two major patterns in Africa: Hepatitis C virus (HCV) 
related in Egypt, north of the Sahara, and Hepatitis B 
Virus (HBV) related in sub-Saharan countries(6). 
Moreover, it occurs at earlier age in Africa, at a median 
of 45 years  and with advanced stage(5). HCC control 
in Africa is a daunting prospect because of lack of 
awareness about risk factors and equipped facilities in 
terms of human power and infrastructure (6). 
 
In Ethiopia, HCC is the eighth most common cancer 
with 100% fatality rate among males (7). Most of the 
HCC cases in low income countries like Ethiopia die 
within few months (<2.5 months) following diagnosis. 
This might be due to lack of facility for cancer 
screening ,lack of skill to differentially diagnose HCC 
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from other diseases and late arrival of cases in seeking 
medical care (4,7). 
 
Observation of HCC case struggling to live with HCC 
prompted us to review associated situations and 
countries’ response to it.  Moreover, there is lack of 
information on the burden, risk factors, diagnosis 
modalities, surveillance strategies and treatment 
approaches to HCC in Ethiopia. 
 
Thus, the purpose of this review was to analyze 
existing evidence related to burden, risk factors, 
diagnosis modalities, surveillance strategies, and 




Eligibility Criteria:  Studies that assessed the HCC 
proportion, clinical and laboratory features, associated 
factors, diagnostic methods, treatment and prevention 
 strategies in Ethiopia were included. Those papers 
published in English Language were reviewed. 
 
Search Methods: Literatures were 
retrieved from electronic database of PubMed and 
Cochrane library between September/2016 and January 
2/2017 using key words and mesh terms related to 
HCC prevalence, diagnostic modalities, and treatment 
and prevention strategies in Ethiopia .The key 
words include ‘hepatocellular carcinoma’, ‘hcc’, ‘hepat
oma’, ‘malignant hepatoma’, ‘hepatocarcinoma,’magni
tude’, ‘prevalence’,’proportion’,‘clinical diagnosis’, ‘la
boratory diagnosis’,’radiological diagnosis’,’pathologic
al diagnosis’,’Treatment’, ‘control’, ‘prevention’, ‘Ethi
opia’. The search was limited to articles published in 
English language in human subject (Table 1). 
Moreover, we also hand searched articles, guidelines 
and reviews from World Health Organizations (WHO), 
lancet and Google scholar. 
  
Table 1: Search strategy used to retrieve appropriate literatures using Mesh terms, Bahir Dar, Ethiopia, 2017. 
Database/  
Search date 
Search strategy/mesh terms Number of 
papers 
retrieved 
Cochrane Database of 
Systematic Reviews: 
Issue 12 of 12, 
December 2016/ 
 
Sep 1/2016 - January  
2/2017 
#1"hepato-carcinoma":ti,ab,kw or "HCC":ti,ab,kw or "hepatoma":ti,ab,kw and 
"Ethiopia" with Hepato-Biliary Group in Review Groups (Word variations have been 
searched) 
#2"hepatocellular carcinoma":ti,ab,kw or "HCC":ti,ab,kw or "hepatoma":ti,ab,kw and 
"diagnosis":ti,ab,kw and "Ethiopia":ti,ab,kw with Hepato-Biliary Group in Review 
Groups (Word variations have been searched) 
#3"hepatocellular carcinoma":ti,ab,kw or "HCC":ti,ab,kw or "hepatoma":ti,ab,kw and 
"treatment":ti,ab,kw and ethiopia:ti,ab,kw with Hepato-Biliary Group in Review 
Groups (Word variations have been searched) 
(#1and #2 and #3) 
524 
PubMed/  
Sep 1/2016 - January  
2/2017 
(((("Carcinoma, Hepatocellular"[Mesh]) OR "HCC1 autoantigen" [Supplementary 
Concept]) OR ( "Adenoma, Liver Cell"[Mesh] OR  "Liver Neoplasms, 
Experimental"[Mesh] )) AND ( "Cross-Sectional Studies"[Mesh] OR "epidemiology" 
[Subheading] OR "Epidemiology"[Mesh] OR  "Prevalence"[Mesh] )) AND 
"Ethiopia"[Mesh] 
5 
(((("Carcinoma, Hepatocellular"[Mesh]) OR "HCC1 autoantigen" [Supplementary 
Concept]) OR ( "Liver Neoplasms, Experimental"[Mesh] OR  "Adenoma, Liver 
Cell"[Mesh] )) AND ( "Diagnosis"[Mesh] OR "Early Diagnosis"[Mesh] OR "Diagnosis, 
Computer-Assisted"[Mesh] OR "Immunologic Tests"[Mesh] OR "Early Detection of 
Cancer"[Mesh] OR "Clinical Laboratory Techniques"[Mesh] OR  "diagnostic imaging" 
[Subheading] )) AND "Ethiopia"[Mesh] 
4 
((((("Carcinoma, Hepatocellular"[Mesh]) OR "HCC1 autoantigen" [Supplementary 
Concept]) OR ( "Liver Neoplasms, Experimental"[Mesh] OR "Adenoma, Liver 
Cell"[Mesh] )) AND "Therapeutics"[Mesh]) OR "prevention and control" 





Study Selection:  All of the identified studies were 
listed. Studies retrieved from PUBMED independently 
assessed the fulfilment of the inclusion criteria by two 
of the authors (Biadglegne F and Derbie A). Studies 
retrieved from Cochrane library independently assessed 
the fulfilment of the inclusion criteria by two of the 
authors (Zenebe Y and Adem Y). Disagreements 
regarding the inclusion or exclusion of publications 
were resolved by discussion. 
 
Critical appraisal of studies for quality:  Two authors 
(Mekonnen D and Biadglegne F) assessed the quality 
of selected studies using the critical appraisal checklist 
published by the critical appraisal skills programme 
(CASP), Oxford, UK(8). We assessed the risk of bias 
by assessing the methodological quality of the studies 
and level of evidence for the research question. 
Disagreements on grading the level of evidences were 
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Table 2:  Critical appraisal of articles included in the review, Bahir Dar, Ethiopia, 2017 
S/N Papers  
(Full Title) 
Level of evidence based on the study 
design 
(High, moderate, low, very low) 
Reflections, concerns, on limitations or 
strengths 
Final evaluation 
on level of 
evidence for our 
research question 
1 A review of 
a five (5) years experience (Sept. 2004-
Aug. 2009) with hepatic resections at Gonda
rUniversity Hospital (GUH). Worku et al  
Ethiop Med J. 2013 Jan;51(1):59-65 
Very low  
Not representative, no history of follow up 
data for other patients’ , service is interrupted 
now 
Very low  
2 Major Risk Factors, Clinical and Laboratory 
Characteristics of Patients With HCC: A 
retrospective Study at Tikur Anbassa 
Hospital, Ethiopia. Mekonnen et al 
Ethiop Med J, 2015 
Very low  
Few sample size, 
Incomplete data, Differential /non differential/ 
bias 
Very low 
3 Hepatitis C virus infection and chronic liver 
disease in Ethiopia where hepatitis B 
infection is hyper endemic. Tsega et al. 
Trans R Soc Trop Med Hyg. 1995 
Very low  
Very small sample size, Too old, selection 
bias, Inconsistency 
Very low  
4 Primary carcinoma of the liver in Ethiopia. A 
study of 38 cases proved at post-mortem 
examination. Pavlica D & Samuel I. Br J 
Cancer. 1970 Mar; 24(1):22-9. 
Very low  
Information bias, Very old data 
No laboratory data   
Very low  
5 Chronic liver disease in Ethiopia: 
A clinical study with emphasis on identifying 
common causes. Tsega et al. Ethiop Med 
J. 1992 Apr;30(2 Suppl):1-33 
Moderate  





Hepatocellular carcinoma in Ethiopia. 
A prospective clinical study of 100 patients. 
Tsega E East Afr Med J. 1977 
May;54(5):281-92 
Low  
Selection bias, Confounding bias, Sampling 
bias, Lost to follow up, No full text article, 
Too old data 
Very Low  
7 Current views on liver diseases in Ethiopia. 
Tsega E Ethiop Med J. 1977 
Very low  
No full article, Sample size not known, Too 
old data 
Very low 
8 Histopathological features of liver disease in 
hospitalized Ethiopian patients. Fekade D. 
Ethiop Med J. 1989  
Very low  
No full text article, Too old data 





Data extraction and management:  The proportions of 
HCC, clinical characteristics, risk/associated/ factors, 
laboratory characteristics presented in the studies were 
collected. Three authors (Mekonnen D, Elfu B and 
Hailu D) extracted all data independently. 
Disagreements on the synthesized data were resolved 
by discussion. In addition, qualitative data were 
collected from 12 senior internists and 4 surgeons 
using them as key informants; to document the current 
practices and help as an illustration to the review. 
Semi-structured questionnaire was used to identify 
gaps and guided the interview (Table 3). Moreover, a 
case history of one 
HCC patient also summarized. Mendley reference 
manager was used to manage citations. 
 
Results  
Study selection:  A total of 1448 literatures were 
retrieved (912 from PubMed, 524 from Cochrane 
library, 5 from lancet, 5 from Google scholar and 2 
from WHO). After removing the duplicates and 
screening, 27 articles were assessed for eligibility 
based on the criteria. Eight studies fulfill the eligibility 
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Table 3: Results of the key informant interviews regarding HCC, Bahir Dar, Ethiopia, 2017 
S/n Discussion points  Summarized key informant responses 
1 Staging system  American Association for the study of Liver diseases (AASLD) 
 Okuda 
 Tumor node metastasis (TNM)  
2 Risk Factors  Liver cirrhosis  
 Chronic infection with Hepatitis B  
 Chronic infection with Hepatitis C viruses  
 Aflatoxin intoxication 
3 Preventions  HBV vaccination 
4 Imaging technique  Ultrasound 
 Computed tomography 
5 Pathological technique    Ultrasound guided fine needle aspiration 
6 Lab Techniques  Alpha-1 fetoprotein 
7 Surveillance Strategies  No Surveillance Strategies 
8 Treatment  No treatment except supportive treatment 
9 National guideline  No 
10 operational policy, strategy 
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Literatures used for 
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Study characteristics:  Eight studies were included in 
the review (Table 4). However, full test article was 
retrieved only for three of the studies (9–11). 
Furthermore, except two studies (9,12), the year of 
publication lies between 1970-1995 G.C which is 
relatively old (10,11,13–16). Except three studies 
(10,11,14), all the remaining are published in Ethiopian 
Medical Journal (9,12,13,15,16). Six studies are 
retrospective and/or cross sectional study in design (9–
12,15,16) and the other two are follow up types 
(13,14).The numbers of participants under each study 
were very small. Mekonnen et al (2015) review basic 
demographic factors, risks, laboratory profiles and 
imaging reports of 51 HCC patients. Of those 39  were 
male and 12 were female with age group ranged 
between 18 to 65 years(9). Tsega et al (1995) studied 
51 males and 17 females HCC patients with mean age 
of  49±13.1 (10). In the Pavlica D & Samuel I  (1970) 
study,  35 male and 3 female were included and their 
age lies between 23-67 years (11). Worku et al (2013) 
report 9 HCC cases with resection history (12). Tsega 
et al (1992) define clinical features and associated  risk 
factor for  112 young male  HCC cases admitted  to 
hospital between July 1986 and April 1989 (13). Tsega 
E (1977) assessed the clinical and laboratory features, 
and associated risk factors of 100 HCC patients, of 
whom one-third were under the age of 40(14). 
Fekade D (1989) analyzed 704 patients’ biopsy done at 
Addis Ababa University hospital with liver diseases; of 
whom HCC accounted 135 (19.2%) of study subjects 
(16) (Table 4). 
 
Risk of bias within and across the studies:  One or 
more types of bias such as information, selection and 
confounding bias were observed within studies (Table 
2). Six studies are retrospective and/or cross sectional 
study in design (9–12,15,16) and the other two are 
follow up types (13,14).The sample size in each study 
was very low. Furthermore, most of the results did not 
use any statistical method and were of qualitative 
reports. Thus, bias is likely high in all reports. There 
was also heterogeneity across studies’ report. 
 
Synthesis of results:  Data on HCC proportion among 
liver disease patients  lies between 16.1% (11) and 
19.2% (16). The clinical feature of HCC patients 
reported were exhaustion, loss of appetite, rapid loss of 
weight, epigastric pain, right upper abdominal quadrant 
(RUQ) pain with a rapidly growing mass, jaundice, and 
ascites with or without hepatomegaly and  
splenomegaly (9,13–15). This, clinical case definition 
is in line with the case reported below. Mr. Mekonnen 
Nigus was a hard working farmer living in rural village 
Raya Kobo Woreda, Amhara National Regional State, 
Ethiopia. He had a history of splenomegally and 
frequent malaria infection at his young age. He didn’t 
have previous history of hepatitis. He sometimes drinks 
local beer. As a farmer, he frequently cultivates and 
harvests Maize, Teff, Sorgum and Pepper. He 
repeatedly visited the nearby health centers for medical 
intervention. However, health professionals diagnosed 
him as gastritis. When his condition worsens, he was 
taken to Dessie private hospital; there, he diagnosed 
with advanced stage of HCC. The physician advised 
his families for house rest and palliative care. His chief 
complaint was exhaustion, loss of appetite, rapid loss 
of weight, epigastric pain, a big, hard, tender and 
grossly palpable nodular liver. Mr Mekonnen Nigus 
died one month after he diagnosed; on June 6, 2015 
G.C at the age of 74 years. 
  
 
                             Mr Mekonnen Nigus (1941-2015 G.C). 
 
 
Except two studies, the remaining six studies reported 
one or more associated factors for HCC (9–11,13–15).  
Cirrhosis as a risk factor for HCC have been reported 
by four studies (11,13–15) and  hepatotoxic indigenous 
drugs by three studies (11,14,15), viral hepatitis by 
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Table 4: Summary of local scientific evidences on HCC Bahir Dar, Ethiopia, 2017 
Authors, year of 
publication 
     Papers (Full title) Major findings 
Mekonnen et al 
2015 (9) 
 
 Major Risk Factors, Clinical and 
Laboratory Characteristics of Patients 
With HCC: A retrospective Study at Tikur 
Anbassa Hospital, Ethiopia 
Risk Factors 
 Hepatitis B and C viruses =48% 
 History of alcohol abuse was =45%  
Clinical features 
 right upper abdominal pain =88.2 % 
 as cites =21.6 % 
 portal vein thrombosis =41.2 % 
 hepatomegaly=70.6 % 
 splenomegaly =19.6 % 
Laboratory characteristics; AFP level of 
 500 = 19 (43.2 %) 
 < 20 =11 (25 %) 
 200-500= 8 (18.2 %) 
Tsega et al 
1995(10) 
 
Hepatitis C virus infection and chronic liver 
disease in Ethiopia where hepatitis B 
infection is hyper endemic. 
 For both HBV and HCV their association with 
HCC was not significant, P>0.05 
Pavlica D & 
Samuel I 1970 
(11)  
Primary carcinoma of the liver in Ethiopia. 
A study of 38 cases proved at post-
mortem examination 
Proportions 
 38/236 HCC cases identified 
 PHCC account for 20%death in medical ward 
Associated factors 
 Cirrhosis 
 Histotoxic agents like Mycotoxin and indigenous 
drugs 
Worku et al 
2013 (12) 
A review of a five (5) years of 
experience (Sept. 2004-Aug. 2009) 
with hepatic resections at Gondar 
University Hospital (GUH) 
Proportion 
 2/9 resections death reported 




Chronic liver disease in Ethiopia: 
a clinical study with emphasis on  
identifying common causes 
Clinical Features 
 Exhaustion, loss of appetite, rapid loss of 
weight, epigastric pain, a big, hard, tender and 
grossly nodular liver with bruit, signs of portal 
hypertension, and/or hepatic encephalopathy 
Laboratory Features 
 Serum anti-nuclear factor, anti-mitochondrial 
anti-bodies and anti-smooth muscle anti-bodies 
were absent 
 Hepatitis B virus markers =78% HCC patients 
 The HBsAg carrier state =23% 
 58 (52%)  HCC have >500 mg/ml AFP  
Risk Factor 
 85% of HCC =macro nodular cirrhosis 
 
 
Tsega E 1977 
(14) 
 
Hepatocellular carcinoma in Ethiopia.Apro
spective clinical study of 100 patients 
Clinical Features 
 Upper abdominal pain with a rapidly growing 
mass, jaundice, and ascites  
 In 12 patients, fever was the primary admission 
complaint.  
 Hepatic bruit over an enlarged liver =80% of 
patients  
 Liver function tests and analysis of ascitic fluid 
were unpredictable.  
 None of the paraneoplastic syndromes were 
observed in the 100 patients.  
Laboratory Features 
 65% of the patients but none of the control 
group were positive for alpha-fetoglobulin.  
 50% of the patients and 7% of the control 
subjects had demonstrable HBsAg in their sera 
(p<0.001). 
Risk Factors 
 Medicinal herbs and/or dietary hepatotoxins 
 Viral hepatitis  
 Cirrhosis  




Current views on liver diseases in Ethiopia Clinical Features 
 Anorexia, weight loss, persistent, burning, right 
upper quadrant pain, and a hard, nodular, tender 
RUQ mass. Over 5% of malignancies seen were 
HCC 
Risk Factors 
 viral hepatitis,  cirrhosis, Herbal medicines, 
aflatoxins 
Fekade D 1989 
(16) 
Histopathological features of liver disease 
in hospitalized Ethiopian patients 
Proportion 
HCC for accounted 135 (19.2%)  of all diagnoses 
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Key informants interview result showed that different 
staging system is used by different clinicians due to 
lack of governing guideline. Moreover, liver cirrhosis, 
HBV, HCV and afla toxin intoxication mentioned as a 
risk factor. There are no regular surveillance activities. 
Furthermore, there is no policy framework and national 
guideline for management of HCC (17). Alfa feto 
protein (AFP) was the most widely used diagnostic 
marker; Ultrasound (US) guided fine needle aspiration 
was rarely used (Table 3). 
 
Discussion 
Updated scientific literatures regarding the HCC 
epidemiology, risk factors and clinical and laboratory 
characteristics in Ethiopia is very limited. Moreover, 
diagnostic modalities, surveillance strategies, and 
prevention and treatment options are none. Only eight 
literatures identified, of which six are too old to 
represent the current situation. Moreover, the studies 
were very limited in scope; focused on prevalence, 
clinical markers for HCC and associated factors (Table 
2). Furthermore, studies were retrospective in design 
with very small subjects. Despite that, our review 
showed that HCC is clinically, a well characterized 
disease and shouldn’t confused with other diseases. 
However, according to the case reported here, they 
often miss diagnosed (13). This might be due to lack of 
awareness about HCC among low and middle level 
health professionals. 
 
The proportion of HCC among patients with liver 
disease was between16.1% (11) and 19.2% (16). 
However, these studies used small sample size; lack 
appropriate methodology, and too old to represent the 
current prevalence. Thus, both institution and 
community based survey is required to clearly show 
the incidence and prevalence of HCC in Ethiopia. 
 
According to this review, Cirrhosis (11,13–15)  
followed by  hepatotoxic indigenous drugs (11,14,15) 
and  viral hepatitis  were found to the major risk factor 
for HCC in Ethiopia. Moreover, data from our 
informants review showed that liver cirrhosis, chronic 
infection with HBV and HCV, and aflatoxin were the 
major associated factors with HCC. Unlike our review 
and key informant report, recent data emerged from 
lancet emphasizing the role of viral hepatitis (5,6) and 
underscore the role of hepatotoxic indigenous drugs 
and aflatoxin. 
 
Data on the prevalence of HBV were surplus and lies 
between 3.7and 16.8% (18). Different small scale cross 
sectional study showed the increased rate of HCV 
which lies between 3.6 to 10 % (19–23). One study in 
Ethiopia aimed at analyzing the levels and frequency of 
AFT contamination in consumed cereals using a total of 
595 food samples (24). Aflatoxin B and G was the 
predominant form, 30% and 6%, respectively. The 
highest levels of AFB were observed in peanut and 
sorghum samples (24).  Thus, large scale follow up 
study is mandatory to identify the prevailing factors in 
Ethiopia. 
 
Data on diagnostic modalities used in Ethiopia are 
none in our review except AFP. The key informant 
interview report showed that US and AFP frequently 
used diagnostic modalities among presumptive liver 
disease patients in Ethiopia. However, the use of 
biopsy as a diagnostic tool is discouraged. This might 
be due to lack of technically equipped pathologists 
and/or lack of pathologist. Moreover, it should be 
always guided with US and only recommended for 
lesions larger than 1 cm (25–27). Furthermore, with 
biopsy, there is  inherent limitation in differentiating 
between high-grade dysplastic nodules and HCC (25–
27). And  also in patients with indeterminate biopsy 
result, repeat biopsy and/or imaging are recommended 
(28). Thus, the use of biopsy is very limited. Computed 
topography (CT) and magnetic resonance Imaging 
(MRI) was only found in a few health facilities (Table 
3). 
 
Except some beginning at the University of Gondar 
(12), there was no any treatment modalities (Table 3, 
4). This might be due to resources constraints, 
competitive priorities of the country, less political 
commitment to fight HCC and lack of policy 
recommendations by the scientific communities.  Most 
of early detected HCC cases referred to other countries 
like South Africa, Thailand and India which are 
unaffordable. With this experience, most people 
consider HCC as diseases of death penalty. However, 
as part of HCC prevention, HBV vaccination was 
integrated in to the national immunization programme 
since 2007 (29) and currently reaches to 72% coverage 
in infant (17). 
 
Like Ethiopian data, the global epidemiology showed 
that cirrhosis is the prime risk factor for HCC 
development (30,31). Cirrhosis is defined as the 
fibrosis of the liver cells and characterized by 
decreased proliferation and loss of regenerative 
capacity. Approximately 80% of the HCCs develop in 
cirrhotic livers (30). Additional promoting factors 
include, shortening of telomere (31–35), activation of 
satellite cells (36), loss of function of the p53 tumor 
suppressor gene (37), inactivation of the p27 cell cycle 
regulator (38), loss of heterozygosity of the insulin-like 
growth factor 2 receptor locus (39), and loss of protein 
expression of the p16 cell cycle inhibitor (38,39). 
 
 Hepatitis B virus is the second associated factors for 
HCC in three different ways. First, its chronic nature of 
infection leads to cirrhosis (40). Second, HBV-host 
genome integration leads to mutation (31,39,41) and 
third, by producing HBx protein. HBx protein inhibits 
P53, apoptosis and repair system (39,42,43). Of the 
genotypes,  C and D carries two to three fold higher 
risk for developing HCC (44–50). 
 
Hepatitis C virus is another virus associated with HCC. In the 
presence of alcohol, there will be greater HCV  replication, 
changes in the hyper variable region of the viral 
genome, resistance to interferon therapy and inhibition 
of hepatic expression of Bcl-2, resulting in increased 
apoptosis and more severe liver injury and increased 
oxidative stress (39,51). The non-structural proteins of 
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HCV; NS3, and NS5A are key mediators for these role 
(39). Chronic consumption of more than 80 g of 
ethanol per day for more than 10 years increased the 
risk of HCC 5-fold in men and 10 g/day in women are 
associated with 24-fold risk for the development of 
HCC (47,52). HCC accounts 25% of all liver deaths in 
human immunodeficiency virus (HIV) patients. 
Moreover, there are reports indicating HCC developing 
in HIV/HCV co-infected patients to be more 
aggressive, to present at an earlier age and to be less 
curable than HCV mono infected patients. However, a 
direct oncogenic effect of HIV is not clearly defined 
yet (53,54). 
 
Aflatoxin is a class of mycotoxins produced by moulds of 
the Aspergillus parasiticus and Aspergillus flavus. Aflatoxin 
B1 (AFB1) is the most potent naturally occurring 
chemical liver carcinogen and it accounts 4.6-28.2% of 
all HCC cases  (55). Aflatoxins grow on whole grains such 
as rice, corn and wheat as well as on peanuts, almonds, 
walnuts, sunflower seeds, and spices such as black pepper 
and coriander (30). 
 
Studies also demonstrate the link between HCC and 
overweight, obesity, diabetes, hereditary 
hemochromatosis (HH), oral contraceptives, and tobacco 
smoking (56–58). If an obese person chronically 
infected with HBV and /or HCV, there is 100 fold 
increased risk of HCC (56–59) .Literatures showed a 200-
fold increased risk of HCC among  patients with HH (60). 
 
Studies demonstrate that being male (61–63) and 
younger age especially children in developing 
countries (38)  are more affected. In women, estrogen 
effects might suppress interleukin (IL)-6-
mediated inflammation that, reduce both liver injury an
d compensatory proliferation. on the contrary, in men, 
testosterone effects could increase androgen receptor 
signaling, promoting liver cell proliferation (64, 65). 
 
The diagnostic modalities of HCC are based on various 
imaging techniques, histological analysis and serum 
markers. Scientific literatures outside Ethiopia dictate 
widely use of latest and improved imaging techniques. 
The most commonly used imaging techniques are 
summarized in Table 5. 
 
Alpha-1 fetoprotein is a protein that can be expressed 
by hepatic cancer cells, with extremely complicated 
biologic activities. Studies have shown that AFP plays 
double roles in both inhibiting the immune system and 
promoting the growth of cancer cells. Thus, an 
increased in the serum concentration of AFP is 
primarily used as a tumor marker for HCC evaluation 
(68). However, AFP can be elevated in other primary 
liver malignancies and become within normal limits in 
a large proportion of patients with known HCC (69–
72). Due to its low specificity, AASLD didn’t 
recommend AFP in the diagnosis of HCC (72,73). 
However, other literature recommended AFP for 
monitoring of recurrent disease. Because successful 
removal of tumor by surgical means is usually 
followed by an immediate fall in AFP levels to normal 
values in 3–5 days (74,75). A level of 400-500 ng/ml 
was considered diagnostic (66). Other candidate serum 
markers used globally are listed in table 6. 
 
Table 5: Comparative use of imaging techniques for diagnosis of HCC, Bahir Dar, Ethiopia, 2017 (66,67) 
Ultrasound scanning  Screening test and not a diagnostic test 
Colour Doppler Ultrasound Gives the mean velocity of blood flow within a vessel by 
color coding the flow, Better than US 
Contrast enhanced ultrasound  Used to improve sonographic visualization of hepatic 
tumor vascularity 
Multiphasic helical computed tomography  Deemed the imaging technique of choice for the detection 
and staging of HCC 
Magnetic resonance imaging Accurate than CT or US in detecting HCC and estimating the 
actual tumor size 
Multi-detector helical computed tomography  Better than MRI for early detection of small HCC during the 
follow-up of patients with chronic hepatitis and cirrhosis 
Angiography Often used to delineate hepatic anatomy before resection or 
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Table 6: Serum markers for HCC, Bahir Dar, Ethiopia, 2017 (66)  
 Lectin reactive AFP (AFP-L3) 
 Des-gamma carboxyprothrombin (DCP) 
 α-L-fucosidase 
 Glypican-3 
 Squamous cell carcinoma antigen (SCCA) 
 Golgi protein 73 (GP73) 
 Hepatocyte growth factor (HGF) 
 Transforming growth factor-b1 (TGF-b1) 
 Vascular endothelial growth factor (VEGF) 
 Serum proteomics 
 
HBV vaccination is the most effective measure to avert 
HCC. Vaccine against HCV is not yet available and 
would be an active area of research. Reports showed 
that IFN (76–78) and Lamivudine (79,80) reduces the 
risk of HCC. 
  
Many studies have reported the positive and negative 
association of some foods with HCC. Coffee (81,82)  tea (83) 
, vegetables and fruits  (84) consumption have shown to 
reduce HCC. Vitamin K2 inhibits the growth of 
hepatoma cells, by causing cell-cycle arrest and 
apoptosis through different mechanisms (85). 
 
Different surveillance strategies applied for detection 
of very early stage HCC (86) (Table 7). Surveillance 
by US, CT, MRI was employed by most developed 
nations for screening every 6-12 months (78). And also 
some countries used a combination of AFP and US for 
HCC surveillance in clinical practice (87). The most 
appropriate subject but not limited includes: HBV and 
HCV carriers, primary biliary cirrhosis, genetic 
chromatosis and alpha-1- antitrypsin deficiency 
(62,88). Optimal interval of surveillance is around 3-12 
months (88). 
HCC is curative diseases with timely treatment. 
Curable treatments include resection, liver 
transplantation and percutaneous local ablative 
treatment. These are appropriate for asymptomatic 
patients with very early and early stage of HCC. Trans 
-arterial chemo embolization is indicated for patients 
with asymptomatic, multi-nodular HCC (intermediate, 
or stage B), whereas chemotherapy with Sorafenib is 
the only recommended treatment for patients with 
advanced (stage C) HCC. The best supportive care is 
recommended for patients with terminal (stage D) HCC 
(89,90) (Table 7). 
 
Immunotherapy is a new field of liver immunology 
which aimed at treatment of HCC using immunological 
cells, immune mediators and other HCC biomarkers. 
Adoptive immune therapy work by introducing 
effective immune cells to directly remove tumor cells 
(91,92).To date immunotherapy showed at least some 
benefits when combined with other treatment 
modalities such as chemotherapy and curative therapies 
(93). More is to come in the near future in the field of 
immunotherapy. 
 
Table 7: Staging system and treatment strategy of HCC, Bahir Dar, Ethiopia, 2017 (66) 








 Child-Pugh A 
 Asymptomatic  
 single lesion < 2cm 
 No portal hypertension 
 
 Single lesion > 2 cm 
or  
 3 nodular lesions,ea
ch < 3 cm  
 Asymptomatic  
 One, large lesion  
  AMD  
 No vascular invasion 
 No EH lesions 
 Symptomatic 
tumours and/or  
 Invasive tumours 
or  
 EH involvement 
 Severe  HD 
 Child-Pugh C 
Treated By:   resection Resection, percutane
ous ablation, transpla
ntation 
 TACE Sorafenib  Symptomatic 
treatment 
 The 5-year survival 
is > 90% and  
 The tumor rarely 
recurs 
Five-year survival 
>50% after curative 
treatment  
 Survival≈ 16M. 
 palliative care 
 Survival ≈10.7 M. 
 palliative care 
 Survival<6 M.  
 No intervention 
 Symptomatic  
 
BCLC: Barcelona clinic liver cancer staging system; 
AMD: Asymptomatic multifocal disease; TACE: 
Trans-catheter arterial chemoembolization; M: 
Months; EH: Extra hepatic; HD: hepatic dysfunction. 
 
Limitation 
The scopes of studies were limited and assessed only 
clinical characteristics, laboratory features, proportion 
of HCC and associated factors. Methodologically, there 
is also inherent limitation. Moreover, studies are too 
old and used very small sample size. Thus, they were 
unable to represent the current situation. 
 
Conclusions: 
Literatures regarding HCC in Ethiopia are very limited 
and suffer from representativeness. Facilities are 
limited, trained human resource is also quite limited. 
The country has no any policy framework and 
guideline for management of HCC. On the other hand, 
according to unpublished hospital reports, HCC and 
other types of cancer are alarmingly increasing. 
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Sensitive and specific and affordable point of care 
diagnostic technologies is one of the urgent needs for 
HCC control. Besides diagnosis issue, treatment 
options are also not available in our country indicating 
that much efforts is need to bring hopes to affected 
populations. 
 
These seems a decade assignment for the country. 
Thus, the country should have cross-cutting strategies 
to avert the situation. Based on the information 
obtained from our review, we forwarded the following 
recommendations:  
First, in the absence of well-organized health facilities 
and early screening strategies, timely information on 
prevention and control mechanism is the most cost 
effective means of reducing HCC risk factors. This can 
be addressed through health education on alcohol 
misuse, metabolic syndromes (diabetes, overweight 
and obesity), infection prevention of HBV and HCV, 
fruit and vegetable intake, prevention of food 
contaminations by AFT. These healthy life style 
education package can be spread to the communities by 
community leaders, health extension workers, local 
opinion leaders, community radio programs, faith 
based organizations, social media, anti-cancer 
associations and annual scientific 
conferences. Moreover, communities must be made 
aware of HCC, of its possible symptoms, and of the 
necessity of early diagnosis to ensure that HCC is 
curable if identified early. 
 
Second, HBV vaccination should be expanded to all 
eligible risk groups. Moreover, diagnostic services 
must be expanded for earlier identification. 
 
Third, there should be political commitment to improve 
health systems and invest wisely in cancer services. 
Regional cancer centers should be established and 
enabled for full range of services. 
 
Fourth, sustained capacity building skim should be 
established. There should be task shifting from 
oncology to trained physicians and nurses, from 
radiology to radiography technicians and from 
pathologist to laboratory technologists. 
 
Fifth, the current investments on chemicals, pesticide, 
fertilizers and brewery industry should be monitored 
for their environmental friendliness. Farmers should be 
aware on how to handle pesticides and fertilizers. 
Environmental biotechnology should be functional to 
monitor the environment from mutagenic chemical and 
plastic wastes. 
 
Sixth, forming care and treatment guidelines should be 
a major part of the strategy to reduce cancer related 
mortality in Ethiopia. 
 
Curbing cancer epidemic should not be the 
responsibility of only to health professionals and 
governments. Rather, it should be national agenda. 
Health professionals, biotechnologists, engineers, 
agricultural professionals, chemists, musicians and 
poets and many more should consort together. 
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